Christina Justenhoven

Christina Justenhoven

Auto-generated profile, based on publicly available information

Christina Justenhoven

Cancer Registry of Rhineland-Palatine

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2010 in Cancer
Verified
Journal Article
Open access
PDF file
CJChristina Justenhoven
Christina Justenhoven
SWStefan Winter
Stefan Winter
UHUte Hamann
Ute Hamann
SHSusanne Haas
Susanne Haas
HFHans‐Peter Fischer
Hans‐Peter Fischer
FNFor The Genica Network
For The Genica Network
BACKGROUND: CYP3A enzymes, due to their role in the metabolism of steroid hormones, are suggested to affect carcinogenesis of hormone‐related cancers. The purpose of the present study was to evaluate the association between polymorphisms located in CYP3A43, breast cancer risk, and tumor characteristics.METHODS: A 3‐plex matrix‐assisted laser desorption ionization time of flight mass spectrometry assay has been established for CYP3A43_74_delA (CYP3A43*2A), CYP3A43_1018_C>G (CYP3A43*3), and CYP3A43_1047_C>T (CYP3A43*1B) polymorphisms, and 1021 breast cancer cases and 1015 age‐matched, population‐based controls from the German GENICA collection have been genotyped.RESULTS: No differences in genotype frequencies between cases and controls were observed, indicating that CYP3A43_74_delA is not associated with breast cancer risk. Subgroup analyses showed an association between the CYP3A43_74_delA allele and high‐grade tumors (odds ratio, 1.74; 95% confidence interval, 1.14‐2.65 [P = .010 and Ptrend = .012]).CONCLUSIONS: The data support the notion that the CYP3A43_74_delA variant may result in decreased protein and/or activity levels, and this may further lead to increased hormone levels to promote tumor cell growth and hinder differentiation. Cancer 2010. © 2010 American Cancer Society.

27 January 2022 in Research Square
Verified
Preprint
Open access
PDF file
RSRaja Schirrmacher
Raja Schirrmacher
RHRuben Hamann
Ruben Hamann
CJChristina Justenhoven
Christina Justenhoven
The German Cancer Society (DKG) offers certification of oncological centres since 2003. Meanwhile more than 260 and more than 120 certified centres for breast and prostate cancer, respectively, exist in Germany. Aim of the herein performed investigation was the identification of factors that stimulate treatment of patients with breast or prostate cancer in a certified centre. This study was based on information available in the database of the Cancer Registry of Rhineland-Palatinate, Germany. The impact of age, region of residence, tumor status, grading and presence of metastasis on patient’s decision with respect to a certain medical facility was analyzed by adjusted logistic regression. This investigation included data of 13,020 breast cancer and 10,904 prostate cancer patients diagnosed in the years 2016 to 2020. Overall, 59 % and 28 % of breast and prostate cancer patients, respectively, were treated in a DKG-certified centre. The analyses showed that residence in an urban region was associated with treatment in a certified centre (breast: OR 0.42, 95% CI (0.37-0.48); prostate: OR 0.46 95% CI (0.40-0.53)). In addition, older breast cancer patients were more often treated in hospitals without certificate (OR 1.13, 95% CI (1.04-1.24). Prostate cancer showed no association with age but early tumor stage (T1) were more often treated in hospitals without certificate (OR 1.23, 95% CI (1.03-1.46). In contrast, patients with more advanced tumors, T2 and T3, were likely to be reported by DKG-certified centres (OR 0.58, 95% CI (0.41-0.81) and OR 0.67, 95% CI (0.47-0.96), respectively). Most breast and more than a quarter of prostate cancer patients were treated in DKG-certified centres. The region of residence seemed to affect the decision for a certain facility for all patients. Whereas age at diagnosis and tumor status played a role for breast and prostate cancer patients, respectively.